

CD31 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP7465b

Specification

CD31 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

P16284

CD31 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 5175

Other Names

Platelet endothelial cell adhesion molecule, PECAM-1, EndoCAM, GPIIA', PECA1, CD31, PECAM1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP7465b was selected from the C-term region of human CD31. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CD31 Antibody (C-term) Blocking Peptide - Protein Information

Name PECAM1

Function

Cell adhesion molecule which is required for leukocyte transendothelial migration (TEM) under most inflammatory conditions (PubMed:19342684, PubMed:17580308). Tyr-690 plays a critical role in TEM and is required for efficient trafficking of PECAM1 to and from the lateral border recycling compartment (LBRC) and is also essential for the LBRC membrane to be targeted around migrating leukocytes (PubMed:19342684). Trans-homophilic interaction may play a role in endothelial cell-cell adhesion via cell junctions (PubMed:27958302). Heterophilic interaction with CD177 plays a role in transendothelial migration of neutrophils (PubMed:17580308). Homophilic ligation of PECAM1 prevents macrophage-mediated phagocytosis of neighboring viable



leukocytes by transmitting a detachment signal (PubMed:<a

susceptibility to atherosclerosis (By similarity).

href="http://www.uniprot.org/citations/12110892" target="_blank">12110892). Promotes macrophage-mediated phagocytosis of apoptotic leukocytes by tethering them to the phagocytic cells; PECAM1-mediated detachment signal appears to be disabled in apoptotic leukocytes (PubMed:12110892). Modulates bradykinin receptor BDKRB2 activation (PubMed:18672896). Regulates bradykinin- and hyperosmotic shock-induced ERK1/2 activation in endothelial cells (PubMed:18672896). Induces

Cellular Location

Cell membrane; Single-pass type I membrane protein. Note=Cell surface expression on neutrophils is down-regulated upon fMLP or CXCL8/IL8- mediated stimulation. [Isoform Delta15]: Cell junction. Note=Localizes to the lateral border recycling compartment (LBRC) and recycles from the LBRC to the junction in resting endothelial cells

Tissue Location

Expressed on platelets and leukocytes and is primarily concentrated at the borders between endothelial cells (PubMed:18388311, PubMed:21464369). Expressed in human umbilical vein endothelial cells (HUVECs) (at protein level) (PubMed:19342684, PubMed:17580308). Expressed on neutrophils (at protein level) (PubMed:17580308). Isoform Long predominates in all tissues examined (PubMed:12433657). Isoform Delta12 is detected only in trachea (PubMed:12433657). Isoform Delta14-15 is only detected in lung (PubMed:12433657). Isoform Delta14 is detected in all tissues examined with the strongest expression in heart (PubMed:12433657). Isoform Delta15 is expressed in brain, testis, ovary, cell surface of platelets, human umbilical vein endothelial cells (HUVECs), Jurkat T- cell leukemia, human erythroleukemia (HEL) and U-937 histiocytic lymphoma cell lines (at protein level) (PubMed:12433657, PubMed:18388311).

CD31 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides

CD31 Antibody (C-term) Blocking Peptide - Images

CD31 Antibody (C-term) Blocking Peptide - Background

CD31 is a cell adhesion molecule expressed on platelets and at endothelial cell intercellular junctions.

CD31 Antibody (C-term) Blocking Peptide - References

Simmons D.L., Walker C.J. Exp. Med. 171:2147-2152(1990) Stockinger H., Gadd S.J.J. Immunol. 145:3889-3897(1990)Newman P.I., Berndt M.C.Science 247:1219-1222(1990)